. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: J Ren Nutr. 2019 Jan 21;29(5):428–437. doi: 10.1053/j.jrn.2018.11.002

Table 4.

Comparison of Changes in Anemia and Iron Indices and Anemia Therapies

		SO Therapy
Parameter	Baseline (−Q1; ref)	Q1	Q2	Q3	Q4	P Value
Anemia and iron indices
Ferritin (ng/mL)	988 (22)	1056 (22)^**	1075 (21)^***	1089 (22)^***	1096 (21)^***	<.0001
Transferrin saturation (%)	34.4 (0.5)	35.7 (0.5)^*	35.9 (0.5)^**	36.3 (0.5)^***	35.8 (0.5)^*	.0001
Hemoglobin (g/dL)	10.9 (0.05)	10.9 (0.05)	10.9 (0.05)^***	10.9 (0.05)	10.9 (0.05)	<.0001
Anti-anemia therapy
IV iron sucrose use (%)	78.9	77.7	75.7	69.6^**	72.1^*	.0002
IV iron sucrose dose (mg/month)	75.4 (1.1)	73.5 (1.1)	72.7 (1.1)^*	71.0 (1.1)^***	73.0 (1.1)^*	.001
IV ESA use^† (%)	87.4	85.1	84.5^*	84.3^*	83.2^*	.03
IV epoetin alfa dose (IU/week)	5085 (192)	4675 (193)^**	4790 (195)^*	4830 (202)^*	5012 (215)	.003

ESA, erythropoietin-stimulating agents; IV, intravenous; ref, referent; SO, sucroferric oxyhydroxide.

Values are presented as least-squared mean (standard error) or n (%). P values compare summary estimates across time with −Q1 as the reference. Overall P values were calculated using linear mixed effects regression (continuous variables) or Cochran’s Q test (categorical variables).

P < .05

^**

P < .001

^***

P < .0001 (vs. baseline).

^†

IV ESA use includes epoetin alfa, epoetin beta and methoxy polyethylene glycol, and darbepoetin alfa.